Targeting antioxidant enzymes as a radiosensitizing strategy

Cancer Lett. 2018 Dec 1:438:154-164. doi: 10.1016/j.canlet.2018.09.004. Epub 2018 Sep 14.

Abstract

Radiotherapy represents a major anti-cancer modality and effectively kills cancer cells through generation of reactive oxygen species (ROS). However, cancer cells are commonly characterized by increased activity of ROS-scavenging enzymes in adaptation to intrinsic oxidative stress, leading to radioresistance. Abrogation of this defense network by pharmacological ROS insults therefore is shown to improve radioresponse in preclinical models; some of them are then tested in clinical trials. In this review, we address (1) the importance of ROS in radioresponse, (2) the main systems regulating redox homeostasis with a special focus on their prognostic effect and predictive role in radiotherapy, and (3) the potential radiosensitizers acting through inhibition of antioxidant enzymes.

Keywords: Antioxidant enzymes; Antioxidant system inhibitors; Radiotherapy; Reactive oxygen species.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antioxidants / metabolism*
  • Buthionine Sulfoximine / pharmacology
  • Glutathione / metabolism
  • Homeostasis / drug effects*
  • Homeostasis / radiation effects
  • Humans
  • Models, Biological
  • Neoplasms / drug therapy
  • Neoplasms / metabolism
  • Neoplasms / radiotherapy*
  • Radiation-Sensitizing Agents / pharmacology*
  • Reactive Oxygen Species / antagonists & inhibitors*
  • Reactive Oxygen Species / metabolism
  • Reactive Oxygen Species / radiation effects
  • Superoxide Dismutase / metabolism

Substances

  • Antioxidants
  • Radiation-Sensitizing Agents
  • Reactive Oxygen Species
  • Buthionine Sulfoximine
  • Superoxide Dismutase
  • Glutathione